April 1 (Reuters) - Connect Biopharma Holdings Ltd CNTB.O:
CONNECT BIOPHARMA ANNOUNCES POSITIVE TYPE C MEETING WITH THE FDA FOR RADEMIKIBART
CONNECT BIOPHARMA HOLDINGS LTD - TRIALS EXPECTED TO INITIATE IN Q2 2025
CONNECT BIOPHARMA HOLDINGS LTD - DATA FROM RADEMIKIBART PHASE 2 TRIALS EXPECTED IN H1 2026
Source text: ID:nGNX6n7CSX
Further company coverage: CNTB.O
(((( Reuters.briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.